Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.

@article{Meredith2001IntraperitonealRO,
  title={Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.},
  author={Ruby F. Meredith and Rafael. Alvarez and Edward Partridge and Muhammad B Khazaeli and Ching Yuang Lin and Daniel J. Macey and John H. M. Austin and Larry C. Kilgore and William E. Grizzle and Jeffrey Schlom and Albert F Lobuglio},
  journal={Cancer biotherapy & radiopharmaceuticals},
  year={2001},
  volume={16 4},
  pages={
          305-15
        }
}
A phase I trial was designed to examine the feasibility of combining interferon and Taxol with intraperitoneal radioimmunotherapy (177Lu-CC49). Patients with recurrent or persistent ovarian cancer confined to the abdominal cavity after first line therapy, Karnofsky performance status > 60, adequate liver, renal and hematologic function, and tumor that reacted with CC49 antibody were enrolled. Human recombinant alpha interferon (IFN) was administered as 4 subcutaneous injections of 3 x 10(6) U… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Similar Papers

Loading similar papers…